ERBB2 and neoplasm: Preclinical studies using lapatinib and/or trastuzumab to target HER2 signalling have demonstrated inhibition of AKT signalling [3]; therefore a reduction in p-AKT levels may be a marker of successful HER2 inhibition facilitating subsequent tumour cell death with chemotherapy and HER2-inhibition.